853TiP - Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Renal Cell Cancer
Presenter Reza Elaidi
Citation Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373
Authors R.T. Elaidi1, Y.A. Vano2, N. Aide3, L. Fournier4, D. Deandreis5, F. Tenenbaum6, R. Lebtahi7, H. De Clermont-Galleran8, L. Albiges9, B. Escudier10, F. Joly11, J. Alexandre12, M. Bernardini13, S. Baron14, J. Arfi-Rouche15, C. Noel16, E. Braychenko1, J. O'Quigley17, J. Medioni18, S. Oudard18
  • 1Medical Oncology - Hopital Europeen G. Pompidou, ARTIC, 75015 Paris - Paris/FR
  • 2Medical Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 3Nuclear Medicine, Centre Francois Baclesse, Caen/FR
  • 4Radiology, European Georges Pompidou Hospital, Paris/FR
  • 5Nuclear Medicine, Institut G. Roussy, Villejuif/FR
  • 6Nuclear Medicine, Hôpital Cochin, Paris/FR
  • 7Nuclear Medicine, Assistance Publique - Hopitaux De Paris, Paris/FR
  • 8Nuclear Medicine, CHU de Bordeaux Pellegrin, Bordeaux/FR
  • 9Cancer Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 10Medical Oncology, Institut de Cancérologie Gustave Roussy, 94805 - Villejuif/FR
  • 11Medical Oncology, Centre Francois Baclesse, 14000 - Caen/FR
  • 12Medical Oncology, Hôpital Cochin, 75014 - Paris/FR
  • 13Nuclear Medicine, Hopital European George Pompidou, 75015 - Paris/FR
  • 14Biology, Hopital European George Pompidou, 75015 - Paris/FR
  • 15Radiology, Institut de Cancérologie Gustave Roussy, 94805 - Villejuif/FR
  • 16Radiology, Centre Francois Baclesse, Caen/FR
  • 17Matematic And Statistic, Paris University, Paris/FR
  • 18Medical Oncology Service, Hopital European George Pompidou, 75015 - Paris/FR

Abstract

Background

Presence of bone metastases (BM) is a factor of poor prognosis in metastatic renal cell carcinoma (mRCC). Radium-223 is a bone targeted active short half-life a-emitter approved in prostate cancer. Its activity in mRCC osteolytic lesions is unknown.

Trial design

The proof of concept study EIFFEL is a French multicentric phase I/II designed to assess the value of Radium-223 for treatment of mRCC bone lesions. Main objective is to identify the most-successful dose among 4 activity levels: 27.5, 55, 82.5, 110KBq/kg. Primary endpoints are the 6 weeks dose-limiting toxicity (DLT) for escalation cohort and conditional efficacy upon whole-body MRI (WB-MRI) and NaF-PET scan for expansion cohort. In order to optimize the precision of the results, 4 innovative methods were implemented in a context of early phases: 1) a continual reassessment model is used for the 2 phases and expected to provide an optimal dose ( most efficient activity given the acceptable toxicity) 2) Radium-223 to DLT causal relationship assessment uses an intrinsic imputability score to avoid confounding adverse events for DLT qualification, 3) a modified RECIST for bone lesions upon WB-MRI and NaF-PET (considering the entire bone metastatic burden) is used to monitor efficacy in the expansion cohort and 4) efficacy data gathered during the escalation phase will provide prior hypothesis to define the optimal efficacy threshold for the expansion cohort. Analysis of correlations between Radium-223 biodistribution scintigraphy, longitudinal WB-MRI, NaF-PET, and circulating bone remodeling markers will further address important questions in clinical, imagery, metabolism and nuclear medicine domains. The EIFFEL study should provide a large amount of useful data for evaluation and treatment of bone metastasis in mRCC. Results of phase I are expected Q1 2018 and Q4 2019 for final phase II results.

Clinical trial identification

EURACT # 2014-003774-16 - CODE: EIFFEL

Legal entity responsible for the study

ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie Siège social : Service de Cancérologie Médicale Hôpital Européen Georges Pompidou 20-30, rue Leblanc, 75908 Paris Cedex 15

Funding

Bayer Healthcare

Disclosure

All authors have declared no conflicts of interest.